PL2411506T3 - Hamowanie nowotworu z użyciem ludzkich pochodzących z łożyska komórek nk pośrednich i związki immunomodulujące - Google Patents

Hamowanie nowotworu z użyciem ludzkich pochodzących z łożyska komórek nk pośrednich i związki immunomodulujące

Info

Publication number
PL2411506T3
PL2411506T3 PL10722830T PL10722830T PL2411506T3 PL 2411506 T3 PL2411506 T3 PL 2411506T3 PL 10722830 T PL10722830 T PL 10722830T PL 10722830 T PL10722830 T PL 10722830T PL 2411506 T3 PL2411506 T3 PL 2411506T3
Authority
PL
Poland
Prior art keywords
natural killer
killer cells
human placenta
tumor suppression
immunomodulatory compounds
Prior art date
Application number
PL10722830T
Other languages
English (en)
Inventor
Xiaokui Zhang
Lin KANG
Mohammad Heidaran
Steven Jasko
Andy Zeitlin
Ajai Pal
Robert J. Hariri
Original Assignee
Celularity, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celularity, Inc. filed Critical Celularity, Inc.
Publication of PL2411506T3 publication Critical patent/PL2411506T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
PL10722830T 2009-03-25 2010-03-26 Hamowanie nowotworu z użyciem ludzkich pochodzących z łożyska komórek nk pośrednich i związki immunomodulujące PL2411506T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16344909P 2009-03-25 2009-03-25
EP10722830.6A EP2411506B1 (en) 2009-03-25 2010-03-26 Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
PCT/US2010/028885 WO2010111631A1 (en) 2009-03-25 2010-03-26 Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds

Publications (1)

Publication Number Publication Date
PL2411506T3 true PL2411506T3 (pl) 2019-07-31

Family

ID=42315196

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10722830T PL2411506T3 (pl) 2009-03-25 2010-03-26 Hamowanie nowotworu z użyciem ludzkich pochodzących z łożyska komórek nk pośrednich i związki immunomodulujące

Country Status (12)

Country Link
EP (2) EP3489352A1 (pl)
AU (1) AU2010229711B2 (pl)
CA (2) CA2756594C (pl)
DK (1) DK2411506T3 (pl)
ES (1) ES2713524T3 (pl)
IL (2) IL215228A (pl)
NZ (1) NZ595440A (pl)
PL (1) PL2411506T3 (pl)
PT (1) PT2411506T (pl)
RU (2) RU2742171C2 (pl)
WO (1) WO2010111631A1 (pl)
ZA (2) ZA201106982B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008307633C1 (en) 2007-09-28 2015-04-30 Celularity Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2012009422A1 (en) 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells
AU2014215458A1 (en) * 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
US9931332B2 (en) * 2014-07-30 2018-04-03 University Of Southern California Compositions and methods for treating primary effusion lymphoma
US20220378780A1 (en) * 2019-09-23 2022-12-01 Neonc Technologies, Inc. Pharmaceutical compositions comprising poh derivatives
WO2021155312A1 (en) * 2020-01-29 2021-08-05 Celularity Inc. Placental derived natural killer cells for treatment of coronavirus infections
EP4180049A1 (en) * 2021-11-16 2023-05-17 Ostravska univerzita Therapeutic composition for cancer treatment

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
ES2529190T3 (es) 1996-07-24 2015-02-17 Celgene Corporation 2-(2,6-dioxopiperidin-3-il)-ftalimidas sustituidas por amino para reducir los niveles de TNF-alfa
NZ334148A (en) 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
DE69834257T2 (de) * 1997-04-30 2007-01-04 Klingemann, Hans Natürliche killerzelllinien und verfahren zu ihrer verwendung
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
BR9908811A (pt) 1998-03-16 2000-12-05 Celgene Corp Composto, composição farmacêutica e seu uso no tratamento de mamìferos
ATE306469T1 (de) 1999-03-18 2005-10-15 Celgene Corp Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
WO2000063268A1 (en) 1999-04-16 2000-10-26 Wm. Marsh Rice University Poly(propylene fumarate) cross linked with poly(ethylene glycol)
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
JP2002045174A (ja) 2000-07-31 2002-02-12 Inst Of Physical & Chemical Res ナチュラルキラー細胞増殖法
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
CA2430989A1 (en) 2000-12-06 2002-06-13 Robert J. Hariri Method of collecting placental stem cells
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
EP2316919B1 (en) 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
EP1924250B1 (en) 2004-12-01 2017-01-04 Celgene Corporation Methods and compositions comprising immunomodulatory compounds for use for the treatment of immunodeficiency disorders
JP2008528514A (ja) 2005-01-25 2008-07-31 セルジーン・コーポレーション ４−アミノ−２−（３−メチル−２，６−ジオキソピペリジン−３−イル）−イソインドール−１，３−ジオンを使用する方法及び組成物
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
CA2899923A1 (en) 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
WO2007032634A1 (en) * 2005-09-12 2007-03-22 Industry Foundation Of Chonnam National University A method for production of mature natural killer cell
JP5550235B2 (ja) 2005-12-29 2014-07-16 アントフロゲネシス コーポレーション 胎盤幹細胞集団
KR20080097190A (ko) 2005-12-29 2008-11-04 안트로제네시스 코포레이션 태반 줄기세포의 수집과 보존을 위한 개선된 조성물과 이조성물의 이용 방법
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
CN103356711A (zh) * 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
AU2008307633C1 (en) * 2007-09-28 2015-04-30 Celularity Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells

Also Published As

Publication number Publication date
AU2010229711B2 (en) 2015-06-04
CA2756594C (en) 2021-03-23
ZA201504633B (en) 2020-12-23
NZ595440A (en) 2014-05-30
EP3489352A1 (en) 2019-05-29
RU2742171C2 (ru) 2021-02-02
EP2411506B1 (en) 2018-11-07
RU2642988C2 (ru) 2018-01-29
ZA201106982B (en) 2016-08-31
CA2756594A1 (en) 2010-09-30
RU2018102205A (ru) 2019-02-22
RU2011142911A (ru) 2013-04-27
WO2010111631A1 (en) 2010-09-30
IL215228A (en) 2016-11-30
RU2018102205A3 (pl) 2019-02-22
EP2411506A1 (en) 2012-02-01
IL248842A0 (en) 2017-01-31
ES2713524T3 (es) 2019-05-22
PT2411506T (pt) 2019-03-19
AU2010229711A1 (en) 2011-10-27
IL215228A0 (en) 2011-12-29
DK2411506T3 (en) 2019-03-04
CA3110964A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
IL250316A0 (en) Tissue tumor suppression using human placental perfusate and intermediate natural killer cells derived from human placenta
IL248842A0 (en) Tumor suppression using natural killer cells derived from human placenta and immunomodulatory compounds
EP2579821A4 (en) IMPLANT COMPONENTS AND METHOD
PL2606120T3 (pl) Ludzkie komórki ułatwiające tolerancję i ich zastosowanie
EP2498853A4 (en) PATIENT INTERFACE AND ITS ASPECTS
EP2515946A4 (en) NANOCONJUGATES AND COMPOSITIONS OF NANOCONJUGATES
GB0910811D0 (en) Cochlear implant apparatus and methods
IL219607A0 (en) Compositions and methods for stimulating hair growth
IL218212A0 (en) Therapeutic methods and compositions
EP2485796A4 (en) ELECTRO-THERAPEUTIC STIMULATOR
PL2913395T4 (pl) Nowa ciągła ludzka linia komórkowa
GB0906828D0 (en) Reference electrode and combined electrode
EP2297306A4 (en) HUMAN FACILITATING CELLS
EP2427129A4 (en) DEVICES AND METHODS FOR MODIFYING FABRICS
EP2461870A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
IL216060A0 (en) Ectoparasiticidal methods and formulations
IL216441A0 (en) Ectoparasiticidal methods and formulations
ZA201005770B (en) The treatment of damaged skin
ZA201105502B (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
GB0909085D0 (en) Suppression of nerve cell secretion
GB0907562D0 (en) Response stimulation of fish and the like
AU2010904667A0 (en) Improvements in water disinfection and treatment
AU2010900765A0 (en) Improvements in water disinfection and treatment